A Study of Baricitinib in Healthy Japanese Participants

NCT02263911 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: Baricitinib

Sponsor

Eli Lilly and Company